Moderna stock falls 20% as it slashes guidance on low EU sales, tough U.S. vaccine marketModerna now expects 2024 product revenue to come in between $3 billion and $3.5 billion, down from a previous guidance of $4 billion.[Collection]

Moderna now expects 2024 product revenue to come in between $3 billion and $3.5 billion, down from a previous guidance of $4 billion.https://www.cnbc.com/2024/08/01/moderna-mrna-earnings-q2-2024.html